Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Frequently Asked Questions

What stocks does MarketBeat like better than Brooklyn ImmunoTherapeutics?

Wall Street analysts have given Brooklyn ImmunoTherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brooklyn ImmunoTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,070,000 shares, a decline of 22.5% from the August 15th total of 1,380,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 4.4% of the company's shares are sold short.
View Brooklyn ImmunoTherapeutics' Short Interest.

When is Brooklyn ImmunoTherapeutics' next earnings date?

Brooklyn ImmunoTherapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Brooklyn ImmunoTherapeutics.

How were Brooklyn ImmunoTherapeutics' earnings last quarter?

Brooklyn ImmunoTherapeutics, Inc. (NYSEAMERICAN:BTX) released its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to analyst estimates of $1.75 million.
View Brooklyn ImmunoTherapeutics' earnings history.

Who are Brooklyn ImmunoTherapeutics' key executives?

Brooklyn ImmunoTherapeutics' management team includes the following people:

• Howard J. Federoff, President, Chief Executive Officer & Director
• Sandra Gurrola, Vice President-Finance
• Kevin A. D'Amour, Chief Scientific Officer
• Jay Sial, Chief Administrative & Scientific Officer
• Ronald Guido, Chief Development Officer

Who are some of Brooklyn ImmunoTherapeutics' key competitors?

Some companies that are related to Brooklyn ImmunoTherapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), Repligen (RGEN), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of BTX's competitors.

What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brooklyn ImmunoTherapeutics investors own include CA (CA), Asterias Biotherapeutics (AST), Geron (GERN), Micron Technology (MU), BlackRock (BLK), Endologix (ELGX), OPKO Health (OPK), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP) and Chipotle Mexican Grill (CMG).

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

Who are Brooklyn ImmunoTherapeutics' major shareholders?

Brooklyn ImmunoTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.18%), Cypress Point Wealth Management LLC (1.07%), State Street Corp (0.99%), Vanguard Group Inc. (0.93%), Geode Capital Management LLC (0.81%) and Nuveen Asset Management LLC (0.62%). Company insiders that own Brooklyn ImmunoTherapeutics stock include Charles Cherington and George P Denny III.
View institutional ownership trends for Brooklyn ImmunoTherapeutics.

Which institutional investors are selling Brooklyn ImmunoTherapeutics stock?

BTX stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management LLC. Company insiders that have sold Brooklyn ImmunoTherapeutics company stock in the last year include Charles Cherington, and George P Denny III.
View insider buying and selling activity for Brooklyn ImmunoTherapeutics or view top insider-selling stocks.

Which institutional investors are buying Brooklyn ImmunoTherapeutics stock?

BTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Cypress Point Wealth Management LLC, State Street Corp, Vanguard Group Inc., Geode Capital Management LLC, Nuveen Asset Management LLC, Northern Trust Corp, and Susquehanna International Group LLP.
View insider buying and selling activity for Brooklyn ImmunoTherapeutics or or view top insider-buying stocks.

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $9.48.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics has a market capitalization of $490.40 million.

How many employees does Brooklyn ImmunoTherapeutics have?

Brooklyn ImmunoTherapeutics employs 2,018 workers across the globe.

What is Brooklyn ImmunoTherapeutics' official website?

The official website for Brooklyn ImmunoTherapeutics is www.biotimeinc.com.

Where are Brooklyn ImmunoTherapeutics' headquarters?

Brooklyn ImmunoTherapeutics is headquartered at 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States.

How can I contact Brooklyn ImmunoTherapeutics?

Brooklyn ImmunoTherapeutics' mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (212) 582-1199.